Adherence to clinic recommendations among patients with phenylketonuria in the United States
- PMID: 28162992
- DOI: 10.1016/j.ymgme.2017.01.001
Adherence to clinic recommendations among patients with phenylketonuria in the United States
Abstract
Objective: Assess current management practices of phenylketonuria (PKU) clinics across the United States (US) based on the key treatment metrics of blood phenylalanine (Phe) concentrations and blood Phe testing frequency, as well as patient adherence to their clinic's management practice recommendations.
Methods: An online survey was conducted with medical professionals from PKU clinics across the US from July to September 2015. Forty-four clinics participated in the survey and account for approximately half of PKU patients currently followed in clinics in the US (Berry et al., 2013).
Results: The majority of PKU clinics recommended target blood Phe concentrations to be between 120 and 360μM for all patients; the upper threshold was relaxed by some clinics for adult patients (from 360 to 600μM) and tightened for patients who are pregnant/planning to become pregnant (to 240μM). Patient adherence to these recommendations (percentage of patients with blood Phe below the upper recommended threshold) was age-dependent, decreasing from 88% in the 0-4years age group to 33% in adults 30+ years. Patient adherence to recommendations for blood testing frequency followed a similar trend. Higher staffing intensity (specialists per 100 PKU patients) was associated with better patient adherence to clinics' blood Phe concentrations recommendations.
Conclusion: Clinic recommendations of target blood Phe concentrations in the US are now stricter compared to prior years, and largely reflect recent guidelines by the American College of Medical Genetics and Genomics (Vockley et al., 2014). Adherence to recommended Phe concentrations remains suboptimal, especially in older patients. However, despite remaining above the guidelines, actual blood Phe concentrations in adolescents and adults are lower than those reported in the past (Walter et al., 2002; Freehauf et al., 2013). Continued education and support for PKU patients by healthcare professionals, including adequate clinic staffing, are needed to improve adherence. Future research is needed to understand how to improve adherence to reduce the number of patients lost to follow-up, as the findings of this and similar surveys do not address how to keep patients in clinic.
Keywords: ACMG guidelines; Adherence; Adults; Blood phenylalanine; Phenylketonuria.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors.Pediatrics. 1999 Dec;104(6):e68. doi: 10.1542/peds.104.6.e68. Pediatrics. 1999. PMID: 10586002
-
Diagnostic and management practices for phenylketonuria in 19 countries of the South and Eastern European Region: survey results.Eur J Pediatr. 2016 Feb;175(2):261-72. doi: 10.1007/s00431-015-2622-5. Epub 2015 Sep 8. Eur J Pediatr. 2016. PMID: 26350228 Free PMC article.
-
Metabolic Control of Patients with Phenylketonuria in a Portuguese Metabolic Centre Comparing Three Different Recommendations.Nutrients. 2021 Sep 6;13(9):3118. doi: 10.3390/nu13093118. Nutrients. 2021. PMID: 34578995 Free PMC article.
-
Similarities and differences in key diagnosis, treatment, and management approaches for PAH deficiency in the United States and Europe.Orphanet J Rare Dis. 2020 Sep 25;15(1):266. doi: 10.1186/s13023-020-01541-2. Orphanet J Rare Dis. 2020. PMID: 32977849 Free PMC article. Review.
-
Outcomes beyond phenylalanine: an international perspective.Mol Genet Metab. 2010;99 Suppl 1:S79-85. doi: 10.1016/j.ymgme.2009.09.015. Mol Genet Metab. 2010. PMID: 20123476 Review.
Cited by
-
Pegvaliase dose escalation to 80 mg daily may lead to efficacy in patients who do not exhibit an optimal response at lower doses.Mol Genet Metab Rep. 2022 Aug 1;32:100905. doi: 10.1016/j.ymgmr.2022.100905. eCollection 2022 Sep. Mol Genet Metab Rep. 2022. PMID: 36046394 Free PMC article.
-
Reinstitution of pegvaliase therapy during lactation.Mol Genet Metab Rep. 2022 Nov 17;33:100938. doi: 10.1016/j.ymgmr.2022.100938. eCollection 2022 Dec. Mol Genet Metab Rep. 2022. PMID: 36420422 Free PMC article.
-
The Impact of a Slow-Release Large Neutral Amino Acids Supplement on Treatment Adherence in Adult Patients with Phenylketonuria.Nutrients. 2020 Jul 14;12(7):2078. doi: 10.3390/nu12072078. Nutrients. 2020. PMID: 32674279 Free PMC article.
-
Large Neutral Amino Acid Therapy Increases Tyrosine Levels in Adult Patients with Phenylketonuria: A Long-Term Study.Nutrients. 2019 Oct 21;11(10):2541. doi: 10.3390/nu11102541. Nutrients. 2019. PMID: 31640267 Free PMC article.
-
State-of-the-art 2023 on gene therapy for phenylketonuria.J Inherit Metab Dis. 2024 Jan;47(1):80-92. doi: 10.1002/jimd.12651. Epub 2023 Aug 3. J Inherit Metab Dis. 2024. PMID: 37401651 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous